IONTAS oncology collaboration with IGEM
Our client IONTAS has announced that it will collaborate with IGEM Therapeutics, a UK immune-oncology spin-out from Kings College London, to develop novel immunoglobulin E (IgE) antibodies to treat cancer.
The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase I/IIa study. IONTAS will utilise its proprietary antibody discovery technology to help IGEM identify novel IgE antibodies against two targets.
UK-based IONTAS is a leader in the discovery and optimisation of fully human antibodies.